Table 1.
Baseline characteristics of included trials
| Authors/year | Phase | Total | Age (years) |
No of elderly patients | Treatment arms | Median age (years) | Median PFS | Median OS | Jadad score |
|---|---|---|---|---|---|---|---|---|---|
| Moore et al/200710 | III | 569 | ≥65 | 268 | Gemcitabine + erlotinib Gemcitabine + placebo |
63.7 64 |
3.75 3.55 |
6.24 5.91 |
5 |
| Conroy et al/201123 | III | 342 | ≥65 | 98 | FOLFIRINOX Gemcitabine |
61 61 |
6.4 3.3 |
11.1 6.8 |
3 |
| Rougier et al/201322 | III | 546 | ≥65 | 206 | Gemcitabine + aflibercept Gemcitabine + placebo |
62 61 |
3.7 3.7 |
6.5 7.8 |
5 |
| Von Hoff et al/201321 | III | 861 | ≥65 | 365 | Gemcitabine + nab-paclitaxel Gemcitabine |
62 63 |
5.5 3.7 |
8.5 6.7 |
3 |
| Deplanque et al/201520 | III | 353 | ≥65 | NR NR |
Gemcitabine + masitinib Gemcitabine |
62.6 61.7 |
NR NR |
7.7 7.1 |
3 |
| Neoptolemos et al/201719 | III | 730 | ≥65 | 348 | Gemcitabine + capecitabine Gemcitabine |
65 65 |
13.9 13.1 |
28 25.5 |
3 |
Abbreviations: FOLFIRINOX, oxaliplatin + irinotecan + fluorouracil + leucovorin; NR, not reported; OS, overall survival; PFS, progress-free survival.